James “Jim” Sigg FDA's Deputy Commissioner for Operations and Chief Operating Officer | Official Website
James “Jim” Sigg FDA's Deputy Commissioner for Operations and Chief Operating Officer | Official Website
This is an increase over the number of companies cited in the previous quarter.
The citations in the county include:
- The responsibilities and procedures applicable to the quality control unit are not in writing.
- Written procedures are not followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
- Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
The company cited should take a voluntary action to correct its managing operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality.
Company Name | Area of Business | Inspection Date | Issue Cited |
---|---|---|---|
Playtex Manufacturing - Plant #2, Inc. | Drugs | 04/07/2025 | Procedures not in writing, fully followed |
Playtex Manufacturing - Plant #2, Inc. | Drugs | 04/07/2025 | Written procedures not established/followed |
Playtex Manufacturing - Plant #2, Inc. | Drugs | 04/07/2025 | Computer control of master formula records |
Playtex Manufacturing - Plant #2, Inc. | Drugs | 04/07/2025 | Control procedures to monitor and validate performance |
Playtex Manufacturing - Plant #2, Inc. | Drugs | 04/07/2025 | Scientifically sound laboratory controls |
Playtex Manufacturing - Plant #2, Inc. | Drugs | 04/07/2025 | Investigations of discrepancies, failures |